

AMC ON LOW ENTERPRISE VALUE BASKET IN BIOTECH



PRODUCT STRATEGY

The strategy aims to invest in 10-15 carefully selected companies in a concentrated portfolio. Selection criteria: quality biotech companies with low enterprise value, validated products or pipeline, clearly defined catalysts for value creation, and sufficient cash runway to achieve these catalysts. The strategy aims to outperform its benchmark, the SPDR® S&P® Biotech ETF (“XBI”), on an absolute basis. Potential performance triggers include company-specific positive catalysts within the portfolio, as well as a general return to “risk on” in the market.


FACTS AND FIGURES

Issuer	Bank Julius Baer
Advisor	Sectoral Asset Management Inc.
ISIN	CH1407252803
Currency	USD
Maturity Date	Open End
NAV Date	04.06.2025
NAV	1'043.50
Portfolio Manager Fee (p.a.)	≡ 1%
Issuer Fee (p.a.)	≡ 0.3%
AuM	USD 28'985'300
Components	18


PERFORMANCE

52 week high	1'043.50	52 week low	1'000.00
All-time high	1'043.50	All-time low	1'000.00
Since inception	4.35%		


PRICE CHART




PERFORMANCE MONTHLY



PRODUCT COMPOSITION BY COUNTRY




PRODUCT COMPOSITION BY ASSET CLASS



COUNTRY EXPOSURE MAP

USA	93.33%
Germany	5.98%
USD	0.69%



TOP 5 - BEST PERFORMERS

Name	Short name	Currency	Last price	Performance
------	------------	----------	------------	-------------

RAPPORT THERAPEUTICS INC	RAPP US	USD	12.24	32.94%
BICARA THERAPEUTICS INC	BCAX US	USD	11.01	11.12%
ARCUS BIOSCIENCES INC	RCUS US	USD	10.03	8.96%
TOURMALINE BIO INC	TRML US	USD	18.44	6.15%
ANAPTYSBIO INC	ANAB US	USD	23.52	6.1%

WORST 5 - PERFORMERS

Name	Short name	Currency	Last price	Performance
INSTIL BIO INC	TIL US	USD	29.90	-6.95%
ZENAS BIOPHARMA INC	ZBIO US	USD	9.52	-4.59%
PALVELLA THERAPEUTICS INC	PVLA US	USD	24.44	-4.06%
IMMATICS NV	IMTX US	USD	5.88	-4.01%
SOLID BIOSCIENCES INC	SLDB US	USD	3.50	-1.12%

TOP 5 - LARGEST HOLDINGS

Name	Short name	Currency	Last price	Percentage
RAPPORT THERAPEUTICS INC	RAPP US	USD	12.24	8.24%
BICARA THERAPEUTICS INC	BCAX US	USD	11.01	6.72%
VENTYX BIOSCIENCES INC	VTYX US	USD	1.99	6.23%
MBX BIOSCIENCES INC	MBX US	USD	13.66	6.20%
SOLID BIOSCIENCES INC	SLDB US	USD	3.50	6.18%

IMPORTANT LEGAL NOTICE

IMPRINT This content constitutes marketing material and is not the result of independent financial/investment research. It has therefore not been prepared in accordance with the legal requirements regarding the independence of financial/ investment research and is not subject to any prohibition on dealing ahead of the dissemination of financial/investment research. The information and opinions expressed were produced by Bank Julius Baer & Co. Ltd., Zurich, which is authorised and regulated by the Swiss Financial Market Supervisory Authority FINMA. This content is issued regularly. Information on financial instruments and issuers will be updated irregularly or in response to important events.

STRUCTURED PRODUCTS Frequency of structured-products rating updates The recommendations are not updated on a regular basis but rather depend on their fixed duration.

IMPORTANT LEGAL INFORMATION The information and opinions expressed were valid at the date of writing, may be based on numerous assumptions and, thus, are subject to change without notice. This content serves for information purposes only and is not intended as legal, accounting, or tax advice, or as an offer or invitation to buy or sell financial instruments. The opinions and comments of the authors reflect their current views but not necessarily those of other Julius Baer entities or any other third party. Other Julius Baer entities may have issued, and may in the future issue, other content that is inconsistent with, and may reach different conclusions than, the information presented. Julius Baer assumes no obligation to ensure that such other content be brought to the attention of any recipient of this content. Although the information provided in this content is trusted to be accurate and complete, and data has been obtained in good faith from sources believed to be reliable, no representation or warranty, expressed or implied, is made in this respect. In particular, Julius Baer provides no verbal or written assurances or guarantees with regard to the performance of an asset class or of a financial instrument and does not provide any capital guarantee or capital protection. Furthermore, information provided may not include all relevant information about the financial instruments or issuers referred to. To the extent permitted by applicable laws and/or regulations, Julius Baer accepts no liability whatsoever for any claims for loss or damages of any kind arising directly or indirectly from this content (including acts or omissions by third parties, such as auxiliary persons and/or agents of Julius Baer).

SUITABILITY & SUSTAINABILITY Suitability: Investments in the financial instruments and/or services mentioned may not be suitable for all recipients and may not be available in all countries. Clients of Julius Baer are kindly requested to get in touch with the local Julius Baer entity in order to be informed about the financial instruments and/or services available in their country (w www.juliusbaer.com/locations). Before entering into any transaction, investors should consider the suitability of the transaction to their individual circumstances and objectives. Any investment, trading, or other decision should only be made by the client after a thorough reading of the relevant product term sheet, subscription agreement, information memorandum, prospectus, or other offering document relating to the issue of financial instruments. This content does not constitute a personal recommendation nor take into account specific personal circumstances (e.g. investment objectives, financial situation, or investment strategies). Julius Baer recommends that investors independently assess, with a professional advisor, the specific financial risks, as well as legal, regulatory, credit, tax, and accounting consequences. Where reference is made to a specific research report, this content should not be read in isolation without consulting the full research report, which may be provided upon request.

Sustainability: Depending on the recipient's domicile or place of incorporation, this content may not adhere to any locally applicable existing or proposed principles, laws, rules, or regulations related to the environmental, social, and governance (ESG) criteria. For further details on ESG data, ESG methodology, and the existing legal/regulatory framework, as well as potential implications on financial return and eligible investments, please refer to the 'ESG Disclaimer': www.juliusbaer.com/en/esg-disclaimer

GENERAL RISKS The price and value of, and income from investments in, any asset class mentioned may fall, as well as rise, and investors may not get back the amount invested. Risks involved in any asset class mentioned may include, but are not necessarily limited to, market risks, credit risks, political risks, and economic risks. The investor may be exposed to currency risk when a financial instrument or underlyings of a financial instrument are denominated in currencies other than that of the country in which the investor is resident. The investment, as well as its performance, would therefore be exposed to currency fluctuations and may increase or decrease in value. Investments in emerging markets are speculative and may be considerably more volatile than investments in established markets. This content may include figures relating to simulated past performance. Past performance, simulations, and performance forecasts are not reliable indicators of future results.

SPECIFIC RISKS The prospectus, Key Information Document (KID), and other relevant documents are available free of charge from the local Julius Baer entity (www.juliusbaer.com/locations). In addition, the Key Information Document (KID) can be found at www.juliusbaer.com/product-information

Structured products (e.g. baskets, certificates): These are complex financial products and therefore involve a higher degree of risk. They are intended for investors who understand and are capable of assuming all risks involved. Structured products may therefore only be sold to experienced investors and require additional advice regarding product-specific risks. The value of the products is not only dependent on the development of the underlying, but also on the creditworthiness of the issuer, which may vary over the term of the product. In the event of the issuer's insolvency or bankruptcy, the investors may lose their entire investment in the product.

CONFLICTS OF INTEREST In order to prevent conflicts of interest from adversely affecting the interests of its clients, Julius Baer has established a policy and procedures which are designed to identify and manage such conflicts. These include organisational and administrative arrangements to safeguard the interests of clients. Julius Baer's arrangements include adequate remuneration policies (for persons involved in the production of this content) based largely on qualitative criteria (e.g. the overall quality and accuracy of research) and only remotely on quantitative elements (e.g. the overall performance of Julius Baer). A Julius Baer entity may, to the extent permitted by law, participate or invest in other financing transactions with the issuer of the securities referred to herein, perform services for or solicit business from such issuers, have a position or effect transactions in the securities or options thereof, have any other significant financial interest regarding the issuers of the securities referred to herein, and/or may have done so in the past. For further information about our interest in the investments featured, see the section 'Disclosure & recommendation history' above.

THIRD PARTY INFORMATION This content may contain information obtained from third parties, including ratings from rating agencies such as Standard & Poor's, Moody's, Fitch, and other similar rating agencies, and research from research providers such as MSCI ESG Research LLC or its affiliates, as well as from index providers such as Bloomberg (as defined below). Issuers mentioned

or included in any MSCI ESG Research LLC materials may be a client of, or affiliated with a client of, MSCI Inc. (MSCI) or another MSCI subsidiary. 'Bloomberg' refers to Bloomberg® and Bloomberg indices which are service marks of Bloomberg Finance L.P. and its affiliates, including Bloomberg Index Services Limited (BISL), as well as the administrator of the index. Bloomberg is not affiliated with Julius Baer. The reproduction and distribution of third-party content in any form is prohibited, except with the prior written permission of the related third party. Third-party content providers do not guarantee the accuracy, completeness, timeliness, or availability of any information, including ratings or research, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third-party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third-party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special, or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings or research. Third-party content providers do not approve, endorse, review, or recommend any financial instruments and/or services mentioned. In particular, credit and/or research ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold, or sell securities. They do not address the market value of securities or the suitability of securities for investment purposes and should not be relied on as investment advice.

Sustainalytics ©. All rights reserved. The information, data, analyses, and opinions contained herein: (i) include the proprietary information of Sustainalytics and/or its content providers; (ii) may not be copied or redistributed except as specifically authorised; (iii) do not constitute investment advice nor an endorsement of any product or project; (iv) are provided solely for informational purposes; and (v) are not warranted to be complete, accurate, or timely. Neither Sustainalytics nor its content providers are responsible for any trading decisions, damages, or other losses related to it or its use. The use of the data is subject to conditions available on the Sustainalytics website in the Legal Disclaimers section at the following link: <https://www.sustainalytics.com/legal-disclaimers>

IMPORTANT DISTRIBUTION INFORMATION This content and any market data contained therein shall not be redistributed to any third party unless Julius Baer or the source of the relevant market data gives their approval. This content is not directed to any person in any jurisdiction where (on the grounds of that person's nationality, residence, or otherwise) such content is prohibited. This content may be distributed by the entities listed under the country headings below, with reference to the paragraphs that apply to the entity from which it has been received. European Union: Financial instruments issued by financial institutions (e.g. shares, bank debt securities as well as other claims against financial institutions) are subject to special regulations, such as the Bank Recovery and Resolution Directive, the Single Resolution Mechanism Regulation and related national laws implementing such special regulations. These regulations may have a negative effect on the investment, the investor or the contractual partner of the financial institution in case of a default of the financial institution as a result of the measures that may be undertaken in the process of a resolution of the financial institution. Singapore: This advertisement has not been reviewed by the Monetary Authority of Singapore. This advertisement is distributed in Singapore by Bank Julius Baer & Co. Ltd., Singapore Branch, and is available for accredited investors or institutional investors only. It is not published in connection with an offer of securities or units in investment funds (i.e. collective investment schemes) pursuant to Section 275 or 305, respectively, of the Securities and Futures Act 2001 of Singapore (SFA). Any content relating to the offer or sale, or invitation for subscription or purchase, of securities or investment funds (i.e. collective investment schemes) pursuant to Section 275 or 305, respectively, of the SFA may not be circulated or distributed, nor may such securities or investment funds be offered or sold or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) an institutional investor under Section 274 or 304, respectively, of the SFA, (ii) a relevant person (which includes an accredited investor) or any person pursuant to Section 275(1A) or 305(2), respectively, and in accordance with the conditions specified in Section 275 or 305, respectively, of the SFA, or (iii) otherwise pursuant to, and in accordance with, the conditions of any other applicable provision of the SFA. In particular, for investment funds that are not authorised or recognised by the Monetary Authority of Singapore, units in such funds are not allowed to be offered to the retail public; any written material issued to persons as aforementioned in connection with an offer is not a prospectus as defined in the SFA and, accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply, and investors should consider carefully whether the investment is suitable for them. Please contact a representative of Bank Julius Baer & Co. Ltd., Singapore Branch, with respect to any inquiries concerning this advertisement. Bank Julius Baer & Co. Ltd. (UEN - T07FC7005G) is incorporated in Switzerland with limited liability. UNITED STATES: NEITHER THIS CONTENT NOR ANY COPY THEREOF MAY BE SENT, TAKEN INTO OR DISTRIBUTED IN THE UNITED STATES OR TO ANY US PERSON. © Julius Baer Group, 2024